Satish Garg
Concepts (669)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypoglycemic Agents | 107 | 2026 | 1379 | 17.700 |
Why?
| | Diabetes Mellitus, Type 1 | 158 | 2026 | 3842 | 16.880 |
Why?
| | Blood Glucose | 122 | 2026 | 2312 | 12.990 |
Why?
| | Blood Glucose Self-Monitoring | 73 | 2026 | 699 | 11.750 |
Why?
| | Insulin | 89 | 2026 | 2501 | 10.390 |
Why?
| | Diabetes Mellitus, Type 2 | 59 | 2025 | 2516 | 8.790 |
Why?
| | Diabetes Mellitus | 32 | 2024 | 1092 | 7.350 |
Why?
| | Hypoglycemia | 53 | 2026 | 477 | 6.580 |
Why?
| | Insulin Infusion Systems | 42 | 2026 | 477 | 5.940 |
Why?
| | Monitoring, Ambulatory | 17 | 2017 | 88 | 4.080 |
Why?
| | Myometrium | 9 | 2021 | 38 | 3.970 |
Why?
| | Buffaloes | 11 | 2021 | 12 | 3.960 |
Why?
| | Diabetic Ketoacidosis | 12 | 2024 | 209 | 3.370 |
Why?
| | Spermatozoa | 8 | 2024 | 109 | 3.320 |
Why?
| | Periodicals as Topic | 7 | 2020 | 203 | 3.030 |
Why?
| | Biosimilar Pharmaceuticals | 6 | 2020 | 28 | 2.960 |
Why?
| | Insulin Glargine | 25 | 2022 | 87 | 2.890 |
Why?
| | Hyperglycemia | 17 | 2022 | 374 | 2.860 |
Why?
| | Glycosides | 10 | 2024 | 42 | 2.800 |
Why?
| | Overweight | 6 | 2026 | 606 | 2.780 |
Why?
| | Uterine Contraction | 8 | 2021 | 18 | 2.670 |
Why?
| | Pregnancy in Diabetics | 13 | 2023 | 120 | 2.570 |
Why?
| | Sperm Motility | 7 | 2024 | 35 | 2.460 |
Why?
| | Dog Diseases | 4 | 2021 | 70 | 2.370 |
Why?
| | Insulin Lispro | 14 | 2022 | 42 | 2.340 |
Why?
| | Insulin Aspart | 9 | 2020 | 30 | 2.280 |
Why?
| | Glucagon-Like Peptides | 5 | 2026 | 70 | 2.150 |
Why?
| | Biomedical Technology | 5 | 2023 | 49 | 2.100 |
Why?
| | Mercury | 4 | 2025 | 38 | 2.090 |
Why?
| | Insulin, Long-Acting | 21 | 2022 | 65 | 2.050 |
Why?
| | Humans | 217 | 2026 | 144261 | 2.020 |
Why?
| | Cytokines | 7 | 2021 | 2061 | 1.970 |
Why?
| | Pancreas, Artificial | 5 | 2024 | 97 | 1.960 |
Why?
| | Calcium | 9 | 2024 | 1182 | 1.870 |
Why?
| | Lead | 3 | 2024 | 69 | 1.690 |
Why?
| | Sperm Capacitation | 6 | 2021 | 12 | 1.570 |
Why?
| | Plant Extracts | 5 | 2019 | 187 | 1.570 |
Why?
| | Obesity | 6 | 2026 | 3057 | 1.540 |
Why?
| | Adult | 93 | 2026 | 40262 | 1.510 |
Why?
| | Female | 124 | 2026 | 77976 | 1.470 |
Why?
| | Antioxidants | 5 | 2020 | 549 | 1.450 |
Why?
| | Telemedicine | 6 | 2021 | 940 | 1.450 |
Why?
| | Male | 108 | 2026 | 72035 | 1.410 |
Why?
| | Sepsis | 3 | 2023 | 640 | 1.310 |
Why?
| | Theileriasis | 2 | 2020 | 2 | 1.300 |
Why?
| | Insulins | 2 | 2024 | 38 | 1.290 |
Why?
| | Cattle | 9 | 2024 | 999 | 1.270 |
Why?
| | Animals | 52 | 2025 | 38030 | 1.250 |
Why?
| | Mite Infestations | 2 | 2020 | 9 | 1.230 |
Why?
| | Injections, Subcutaneous | 11 | 2021 | 164 | 1.230 |
Why?
| | Drug Therapy, Combination | 15 | 2026 | 1044 | 1.230 |
Why?
| | Middle Aged | 61 | 2026 | 35762 | 1.200 |
Why?
| | rho-Associated Kinases | 3 | 2021 | 83 | 1.170 |
Why?
| | Calcium Signaling | 3 | 2021 | 251 | 1.150 |
Why?
| | Vasoconstriction | 2 | 2022 | 217 | 1.150 |
Why?
| | Postprandial Period | 5 | 2020 | 115 | 1.120 |
Why?
| | Trace Elements | 2 | 2020 | 52 | 1.090 |
Why?
| | Pre-Eclampsia | 10 | 2023 | 204 | 1.090 |
Why?
| | Diabetes Complications | 5 | 2020 | 220 | 1.060 |
Why?
| | Non-alcoholic Fatty Liver Disease | 2 | 2021 | 265 | 1.040 |
Why?
| | Trypanosomiasis | 2 | 2017 | 5 | 1.030 |
Why?
| | 3-Hydroxybutyric Acid | 3 | 2024 | 17 | 1.020 |
Why?
| | Insulin, Isophane | 6 | 2017 | 22 | 1.010 |
Why?
| | Dermatitis, Atopic | 2 | 2021 | 321 | 1.000 |
Why?
| | Rats, Wistar | 11 | 2020 | 451 | 0.980 |
Why?
| | Pandemics | 5 | 2022 | 1682 | 0.960 |
Why?
| | Protein Kinase C | 2 | 2018 | 252 | 0.960 |
Why?
| | Drugs, Investigational | 2 | 2017 | 31 | 0.960 |
Why?
| | Glucagon-Like Peptide 1 | 4 | 2025 | 145 | 0.920 |
Why?
| | Histamine | 2 | 2017 | 53 | 0.920 |
Why?
| | Acrosome Reaction | 2 | 2024 | 3 | 0.900 |
Why?
| | Pneumonia, Viral | 2 | 2020 | 382 | 0.880 |
Why?
| | Coronavirus Infections | 2 | 2020 | 377 | 0.870 |
Why?
| | Acrosome | 1 | 2024 | 6 | 0.860 |
Why?
| | Dipeptidyl-Peptidase IV Inhibitors | 3 | 2013 | 46 | 0.850 |
Why?
| | Uterus | 6 | 2021 | 226 | 0.820 |
Why?
| | Monitoring, Physiologic | 6 | 2023 | 289 | 0.810 |
Why?
| | Biomedical Research | 8 | 2017 | 709 | 0.790 |
Why?
| | Treatment Outcome | 23 | 2026 | 11643 | 0.790 |
Why?
| | Diabetic Nephropathies | 2 | 2025 | 314 | 0.780 |
Why?
| | Reproducibility of Results | 14 | 2025 | 3403 | 0.780 |
Why?
| | Weight Loss | 4 | 2025 | 832 | 0.760 |
Why?
| | Angiotensin II | 1 | 2023 | 97 | 0.760 |
Why?
| | Spleen | 3 | 2020 | 508 | 0.740 |
Why?
| | Cross-Over Studies | 10 | 2020 | 600 | 0.730 |
Why?
| | Dinoprost | 2 | 2021 | 49 | 0.730 |
Why?
| | Receptor, Notch3 | 1 | 2022 | 8 | 0.730 |
Why?
| | Sulfones | 2 | 2020 | 127 | 0.720 |
Why?
| | Benzamides | 2 | 2020 | 224 | 0.700 |
Why?
| | Administration, Inhalation | 4 | 2018 | 574 | 0.700 |
Why?
| | Aorta | 2 | 2022 | 429 | 0.690 |
Why?
| | Nifedipine | 6 | 2021 | 27 | 0.690 |
Why?
| | Young Adult | 28 | 2026 | 13990 | 0.690 |
Why?
| | Intermediate Filament Proteins | 1 | 2021 | 57 | 0.680 |
Why?
| | Dose-Response Relationship, Drug | 14 | 2020 | 2026 | 0.680 |
Why?
| | Glucose | 6 | 2024 | 1046 | 0.680 |
Why?
| | Type C Phospholipases | 2 | 2018 | 69 | 0.670 |
Why?
| | TRPC Cation Channels | 2 | 2021 | 14 | 0.670 |
Why?
| | Signal Transduction | 6 | 2024 | 5221 | 0.670 |
Why?
| | Arterial Pressure | 1 | 2022 | 135 | 0.670 |
Why?
| | Insulin Antibodies | 2 | 2020 | 103 | 0.670 |
Why?
| | Pregnancy | 23 | 2023 | 7180 | 0.660 |
Why?
| | Trypanosoma | 2 | 2017 | 8 | 0.660 |
Why?
| | Mitochondrial Membranes | 1 | 2021 | 40 | 0.660 |
Why?
| | Biopolymers | 1 | 2020 | 34 | 0.660 |
Why?
| | Dogs | 5 | 2021 | 437 | 0.660 |
Why?
| | Registries | 8 | 2025 | 2382 | 0.650 |
Why?
| | Endometritis | 2 | 2017 | 4 | 0.650 |
Why?
| | Calcium Channel Blockers | 6 | 2021 | 165 | 0.650 |
Why?
| | Theileria annulata | 1 | 2020 | 1 | 0.650 |
Why?
| | Chitosan | 1 | 2020 | 38 | 0.650 |
Why?
| | Diabetic Angiopathies | 6 | 2013 | 254 | 0.650 |
Why?
| | Protein Precursors | 1 | 2021 | 136 | 0.650 |
Why?
| | Copper Sulfate | 1 | 2020 | 8 | 0.640 |
Why?
| | Gelatin | 1 | 2020 | 56 | 0.640 |
Why?
| | Exophthalmos | 1 | 2020 | 17 | 0.640 |
Why?
| | Sodium-Glucose Transporter 1 | 2 | 2017 | 11 | 0.640 |
Why?
| | Betacoronavirus | 2 | 2020 | 285 | 0.630 |
Why?
| | Cattle Diseases | 1 | 2020 | 26 | 0.630 |
Why?
| | Calcium Channels | 2 | 2018 | 154 | 0.630 |
Why?
| | Sulfonylurea Compounds | 2 | 2018 | 50 | 0.630 |
Why?
| | Mutagens | 1 | 2020 | 26 | 0.630 |
Why?
| | Selenium | 1 | 2020 | 49 | 0.630 |
Why?
| | Peste-des-petits-ruminants virus | 1 | 2019 | 1 | 0.620 |
Why?
| | Polyalthia | 1 | 2019 | 1 | 0.620 |
Why?
| | Oleic Acid | 1 | 2020 | 42 | 0.620 |
Why?
| | Aged | 29 | 2026 | 25850 | 0.620 |
Why?
| | Newcastle disease virus | 1 | 2019 | 18 | 0.620 |
Why?
| | Infusions, Subcutaneous | 4 | 2016 | 24 | 0.610 |
Why?
| | Mites | 1 | 2019 | 8 | 0.610 |
Why?
| | Patient Education as Topic | 6 | 2020 | 777 | 0.610 |
Why?
| | Isoproterenol | 1 | 2020 | 96 | 0.610 |
Why?
| | Peroxidase | 2 | 2017 | 168 | 0.610 |
Why?
| | Down-Regulation | 1 | 2022 | 627 | 0.600 |
Why?
| | Potassium Channels | 1 | 2020 | 145 | 0.590 |
Why?
| | Cardiovascular Diseases | 3 | 2025 | 2134 | 0.580 |
Why?
| | Toll-Like Receptors | 1 | 2020 | 194 | 0.570 |
Why?
| | Uterine Artery | 1 | 2019 | 75 | 0.570 |
Why?
| | Oxidative Stress | 4 | 2020 | 1339 | 0.570 |
Why?
| | Adolescent | 33 | 2026 | 22281 | 0.570 |
Why?
| | Endocannabinoids | 2 | 2019 | 57 | 0.560 |
Why?
| | Mercuric Chloride | 1 | 2018 | 2 | 0.560 |
Why?
| | GTP-Binding Protein alpha Subunits, Gq-G11 | 1 | 2018 | 19 | 0.560 |
Why?
| | Biosensing Techniques | 2 | 2018 | 139 | 0.550 |
Why?
| | Voltage-Gated Sodium Channels | 1 | 2017 | 5 | 0.540 |
Why?
| | Tocolysis | 1 | 2017 | 4 | 0.540 |
Why?
| | Eucalyptus | 1 | 2017 | 5 | 0.540 |
Why?
| | Ethanolamines | 1 | 2017 | 14 | 0.540 |
Why?
| | Wound Healing | 1 | 2020 | 351 | 0.540 |
Why?
| | KATP Channels | 1 | 2017 | 17 | 0.540 |
Why?
| | Potassium Channels, Voltage-Gated | 1 | 2018 | 55 | 0.540 |
Why?
| | Vasodilation | 2 | 2019 | 522 | 0.540 |
Why?
| | Weight Gain | 6 | 2024 | 556 | 0.530 |
Why?
| | Oxytocin | 2 | 2016 | 51 | 0.530 |
Why?
| | Interleukins | 1 | 2019 | 248 | 0.530 |
Why?
| | Norepinephrine | 1 | 2018 | 196 | 0.530 |
Why?
| | Immunoglobulin E | 1 | 2019 | 315 | 0.530 |
Why?
| | Double-Blind Method | 9 | 2024 | 2025 | 0.530 |
Why?
| | Hydrogen Sulfide | 1 | 2017 | 48 | 0.520 |
Why?
| | Self Care | 4 | 2013 | 388 | 0.520 |
Why?
| | Endothelium, Vascular | 3 | 2019 | 963 | 0.510 |
Why?
| | NAV1.8 Voltage-Gated Sodium Channel | 1 | 2016 | 3 | 0.510 |
Why?
| | Disposable Equipment | 3 | 2026 | 24 | 0.510 |
Why?
| | Syringes | 3 | 2013 | 49 | 0.510 |
Why?
| | Cadmium | 1 | 2017 | 68 | 0.510 |
Why?
| | Therapies, Investigational | 1 | 2017 | 18 | 0.500 |
Why?
| | Inflammation Mediators | 1 | 2020 | 508 | 0.500 |
Why?
| | Reactive Oxygen Species | 1 | 2020 | 621 | 0.500 |
Why?
| | Coinfection | 1 | 2018 | 141 | 0.500 |
Why?
| | Muscle Relaxation | 1 | 2016 | 28 | 0.490 |
Why?
| | Cholinesterases | 1 | 2016 | 9 | 0.490 |
Why?
| | Mitochondria | 2 | 2021 | 983 | 0.490 |
Why?
| | Minerals | 1 | 2016 | 47 | 0.490 |
Why?
| | Hospitalization | 2 | 2024 | 2424 | 0.490 |
Why?
| | Diffusion of Innovation | 1 | 2017 | 97 | 0.480 |
Why?
| | Receptors, Adrenergic, beta | 1 | 2016 | 61 | 0.480 |
Why?
| | Calcium Channels, L-Type | 1 | 2017 | 117 | 0.470 |
Why?
| | Retrospective Studies | 13 | 2026 | 17009 | 0.470 |
Why?
| | Insulin, Regular, Human | 3 | 2024 | 47 | 0.460 |
Why?
| | Body Mass Index | 8 | 2025 | 2420 | 0.460 |
Why?
| | Ambulatory Care Facilities | 2 | 2023 | 264 | 0.450 |
Why?
| | United States | 18 | 2026 | 15876 | 0.450 |
Why?
| | Vitamins | 1 | 2016 | 178 | 0.450 |
Why?
| | Myocytes, Cardiac | 1 | 2020 | 551 | 0.450 |
Why?
| | Insulin Detemir | 5 | 2017 | 8 | 0.440 |
Why?
| | Gene Expression | 1 | 2020 | 1487 | 0.440 |
Why?
| | Rats | 7 | 2020 | 5592 | 0.420 |
Why?
| | Biomarkers | 12 | 2025 | 4254 | 0.420 |
Why?
| | Drug Delivery Systems | 2 | 2018 | 379 | 0.420 |
Why?
| | Prospective Studies | 14 | 2025 | 7970 | 0.420 |
Why?
| | Drug Administration Schedule | 8 | 2017 | 778 | 0.420 |
Why?
| | Withania | 1 | 2013 | 5 | 0.410 |
Why?
| | Receptors, Adrenergic, alpha-1 | 1 | 2013 | 45 | 0.400 |
Why?
| | Glucagon | 2 | 2022 | 112 | 0.400 |
Why?
| | Antiviral Agents | 1 | 2019 | 767 | 0.400 |
Why?
| | Extracellular Fluid | 1 | 2013 | 36 | 0.390 |
Why?
| | Glucosides | 3 | 2019 | 55 | 0.390 |
Why?
| | Nervous System Diseases | 1 | 2016 | 282 | 0.390 |
Why?
| | Chlorpyrifos | 1 | 2013 | 7 | 0.390 |
Why?
| | History, 21st Century | 3 | 2020 | 219 | 0.380 |
Why?
| | Benzhydryl Compounds | 3 | 2019 | 82 | 0.380 |
Why?
| | Membrane Potential, Mitochondrial | 3 | 2024 | 75 | 0.380 |
Why?
| | Microsomes, Liver | 1 | 2013 | 85 | 0.380 |
Why?
| | Portal Vein | 1 | 2013 | 114 | 0.370 |
Why?
| | Arsenic | 1 | 2013 | 66 | 0.360 |
Why?
| | Time Factors | 12 | 2021 | 7155 | 0.360 |
Why?
| | Myocardial Infarction | 1 | 2020 | 1208 | 0.360 |
Why?
| | Pyrazines | 1 | 2013 | 92 | 0.360 |
Why?
| | Tocolytic Agents | 2 | 2017 | 16 | 0.350 |
Why?
| | Needles | 1 | 2011 | 62 | 0.340 |
Why?
| | Pregnancy Outcome | 3 | 2023 | 476 | 0.340 |
Why?
| | Ascorbic Acid | 1 | 2013 | 179 | 0.340 |
Why?
| | Triazoles | 1 | 2013 | 184 | 0.340 |
Why?
| | Adrenergic beta-Agonists | 2 | 2017 | 91 | 0.340 |
Why?
| | Patient Preference | 1 | 2013 | 221 | 0.340 |
Why?
| | Goats | 2 | 2021 | 25 | 0.340 |
Why?
| | Prevalence | 8 | 2020 | 2815 | 0.340 |
Why?
| | Clinical Trials as Topic | 7 | 2022 | 1050 | 0.320 |
Why?
| | History, 20th Century | 3 | 2019 | 324 | 0.320 |
Why?
| | Blood Chemical Analysis | 2 | 2017 | 108 | 0.310 |
Why?
| | Acetylcholine | 3 | 2019 | 204 | 0.310 |
Why?
| | Nitric Oxide Synthase Type II | 2 | 2022 | 162 | 0.300 |
Why?
| | Calibration | 3 | 2018 | 151 | 0.300 |
Why?
| | Water Pollutants, Chemical | 1 | 2013 | 234 | 0.300 |
Why?
| | DNA Damage | 2 | 2024 | 428 | 0.300 |
Why?
| | Pregnancy Trimester, First | 3 | 2020 | 135 | 0.300 |
Why?
| | Organometallic Compounds | 2 | 2024 | 112 | 0.300 |
Why?
| | China | 4 | 2020 | 269 | 0.290 |
Why?
| | Intention to Treat Analysis | 3 | 2017 | 79 | 0.290 |
Why?
| | 4-Aminopyridine | 2 | 2020 | 30 | 0.290 |
Why?
| | Health Care Costs | 4 | 2016 | 421 | 0.290 |
Why?
| | Reference Values | 6 | 2023 | 797 | 0.290 |
Why?
| | Plant Leaves | 3 | 2019 | 137 | 0.290 |
Why?
| | Child | 14 | 2026 | 22537 | 0.290 |
Why?
| | Research Design | 6 | 2015 | 1129 | 0.280 |
Why?
| | alpha-Tocopherol | 2 | 2020 | 32 | 0.280 |
Why?
| | Prediabetic State | 1 | 2011 | 243 | 0.280 |
Why?
| | Computer Systems | 2 | 2018 | 56 | 0.280 |
Why?
| | Blood Pressure | 4 | 2025 | 1759 | 0.270 |
Why?
| | Veratridine | 2 | 2017 | 5 | 0.260 |
Why?
| | Animals, Newborn | 2 | 2020 | 901 | 0.260 |
Why?
| | Longitudinal Studies | 7 | 2026 | 2926 | 0.260 |
Why?
| | Software | 3 | 2013 | 690 | 0.250 |
Why?
| | Sodium-Glucose Transport Proteins | 2 | 2017 | 3 | 0.250 |
Why?
| | Equipment Design | 4 | 2010 | 530 | 0.250 |
Why?
| | Anti-Bacterial Agents | 1 | 2017 | 1906 | 0.250 |
Why?
| | Nitric Oxide | 3 | 2022 | 897 | 0.250 |
Why?
| | United States Food and Drug Administration | 3 | 2018 | 203 | 0.240 |
Why?
| | Case-Control Studies | 3 | 2026 | 3592 | 0.240 |
Why?
| | Vasodilator Agents | 2 | 2019 | 331 | 0.240 |
Why?
| | Journal Impact Factor | 2 | 2020 | 29 | 0.240 |
Why?
| | Autoantibodies | 3 | 2026 | 1497 | 0.240 |
Why?
| | Hypertension | 4 | 2011 | 1254 | 0.230 |
Why?
| | Risk Factors | 8 | 2024 | 10699 | 0.230 |
Why?
| | Blotting, Western | 3 | 2017 | 1187 | 0.230 |
Why?
| | Ruthenium Red | 2 | 2016 | 7 | 0.230 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2021 | 1217 | 0.230 |
Why?
| | Albuminuria | 3 | 2017 | 187 | 0.230 |
Why?
| | Tissue Culture Techniques | 2 | 2017 | 83 | 0.230 |
Why?
| | Aged, 80 and over | 5 | 2026 | 8243 | 0.230 |
Why?
| | Diabetic Retinopathy | 2 | 2005 | 207 | 0.220 |
Why?
| | Copper | 2 | 2016 | 113 | 0.220 |
Why?
| | Phenylephrine | 2 | 2016 | 75 | 0.220 |
Why?
| | Lipoproteins | 2 | 2019 | 163 | 0.220 |
Why?
| | Large-Conductance Calcium-Activated Potassium Channels | 2 | 2017 | 11 | 0.220 |
Why?
| | Fasting | 1 | 2006 | 276 | 0.220 |
Why?
| | Glomerular Filtration Rate | 3 | 2025 | 758 | 0.220 |
Why?
| | Body Weight | 7 | 2020 | 976 | 0.220 |
Why?
| | Algorithms | 5 | 2018 | 1834 | 0.220 |
Why?
| | Semen Analysis | 1 | 2024 | 13 | 0.210 |
Why?
| | Calcinosis | 4 | 2010 | 233 | 0.210 |
Why?
| | Adrenergic beta-2 Receptor Agonists | 1 | 2004 | 26 | 0.210 |
Why?
| | Exercise | 2 | 2014 | 2193 | 0.210 |
Why?
| | Phosphorylation | 2 | 2020 | 1732 | 0.210 |
Why?
| | Gastric Inhibitory Polypeptide | 1 | 2024 | 13 | 0.210 |
Why?
| | Glucagon-Like Peptide-2 Receptor | 1 | 2024 | 16 | 0.210 |
Why?
| | Cyclic AMP | 1 | 2024 | 208 | 0.200 |
Why?
| | Drug Approval | 1 | 2024 | 89 | 0.200 |
Why?
| | Pyrazoles | 2 | 2018 | 509 | 0.200 |
Why?
| | Uridine Diphosphate | 1 | 2023 | 4 | 0.200 |
Why?
| | Isothiocyanates | 1 | 2023 | 3 | 0.200 |
Why?
| | Thiourea | 1 | 2023 | 41 | 0.200 |
Why?
| | Reproduction | 1 | 2025 | 207 | 0.190 |
Why?
| | Equipment Failure | 2 | 2018 | 115 | 0.190 |
Why?
| | Phthalimides | 2 | 2020 | 2 | 0.190 |
Why?
| | Dietary Supplements | 2 | 2018 | 575 | 0.190 |
Why?
| | Mass Screening | 1 | 2011 | 1332 | 0.190 |
Why?
| | Endocrinology | 2 | 2016 | 75 | 0.190 |
Why?
| | Receptors, Glucagon | 1 | 2022 | 26 | 0.190 |
Why?
| | Vitamin D-Binding Protein | 2 | 2020 | 15 | 0.180 |
Why?
| | Safety | 3 | 2009 | 355 | 0.180 |
Why?
| | Child, Preschool | 6 | 2025 | 11774 | 0.180 |
Why?
| | Ketosis | 1 | 2021 | 12 | 0.170 |
Why?
| | Randomized Controlled Trials as Topic | 5 | 2021 | 1705 | 0.170 |
Why?
| | Reference Standards | 4 | 2017 | 177 | 0.170 |
Why?
| | Testis | 2 | 2025 | 163 | 0.170 |
Why?
| | Mobile Applications | 2 | 2021 | 196 | 0.170 |
Why?
| | Mice | 5 | 2023 | 18329 | 0.170 |
Why?
| | Illinois | 1 | 2021 | 45 | 0.170 |
Why?
| | Immunization, Passive | 1 | 2021 | 87 | 0.170 |
Why?
| | Patient Isolation | 1 | 2021 | 20 | 0.170 |
Why?
| | New York City | 1 | 2021 | 89 | 0.170 |
Why?
| | Los Angeles | 1 | 2021 | 76 | 0.170 |
Why?
| | Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2020 | 49 | 0.160 |
Why?
| | Fluorocarbons | 2 | 2020 | 143 | 0.160 |
Why?
| | Micronucleus Tests | 1 | 2020 | 6 | 0.160 |
Why?
| | Comet Assay | 1 | 2020 | 14 | 0.160 |
Why?
| | Antigens, Viral | 1 | 2021 | 182 | 0.160 |
Why?
| | Interleukin-13 | 1 | 2021 | 144 | 0.160 |
Why?
| | Skin Diseases, Parasitic | 1 | 2020 | 3 | 0.160 |
Why?
| | Patient Satisfaction | 3 | 2015 | 704 | 0.160 |
Why?
| | Progesterone | 2 | 2019 | 255 | 0.160 |
Why?
| | Uncoupling Protein 2 | 1 | 2020 | 9 | 0.160 |
Why?
| | Environmental Exposure | 1 | 2025 | 587 | 0.160 |
Why?
| | Chromium | 1 | 2020 | 17 | 0.160 |
Why?
| | Curcumin | 1 | 2020 | 25 | 0.160 |
Why?
| | Practice Guidelines as Topic | 3 | 2019 | 1559 | 0.160 |
Why?
| | Incidence | 3 | 2017 | 2870 | 0.150 |
Why?
| | Cardiotoxicity | 1 | 2020 | 33 | 0.150 |
Why?
| | Intermediate-Conductance Calcium-Activated Potassium Channels | 1 | 2019 | 1 | 0.150 |
Why?
| | Islets of Langerhans | 1 | 2026 | 832 | 0.150 |
Why?
| | Income | 1 | 2021 | 199 | 0.150 |
Why?
| | Glycemic Index | 2 | 2009 | 26 | 0.150 |
Why?
| | Cyclooxygenase 1 | 1 | 2019 | 26 | 0.150 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2020 | 177 | 0.150 |
Why?
| | Vero Cells | 1 | 2019 | 84 | 0.150 |
Why?
| | Small-Conductance Calcium-Activated Potassium Channels | 1 | 2019 | 13 | 0.150 |
Why?
| | Disease Models, Animal | 2 | 2020 | 4556 | 0.150 |
Why?
| | Lipid Peroxidation | 1 | 2020 | 160 | 0.150 |
Why?
| | Virus Internalization | 1 | 2019 | 65 | 0.150 |
Why?
| | Host-Parasite Interactions | 1 | 2020 | 112 | 0.150 |
Why?
| | Canagliflozin | 1 | 2019 | 10 | 0.150 |
Why?
| | Haptoglobins | 1 | 2019 | 66 | 0.150 |
Why?
| | Tyrosine | 1 | 2020 | 221 | 0.150 |
Why?
| | Diabetes, Gestational | 1 | 2023 | 321 | 0.150 |
Why?
| | Immunity, Cellular | 2 | 2018 | 272 | 0.150 |
Why?
| | Adamantane | 1 | 2019 | 17 | 0.150 |
Why?
| | Area Under Curve | 3 | 2015 | 329 | 0.150 |
Why?
| | Liver Cirrhosis | 1 | 2021 | 288 | 0.140 |
Why?
| | Dipeptides | 1 | 2019 | 57 | 0.140 |
Why?
| | Ion Channels | 1 | 2019 | 129 | 0.140 |
Why?
| | TRPV Cation Channels | 1 | 2019 | 43 | 0.140 |
Why?
| | Congresses as Topic | 2 | 2020 | 221 | 0.140 |
Why?
| | Vitamin D | 2 | 2020 | 399 | 0.140 |
Why?
| | California | 1 | 2020 | 469 | 0.140 |
Why?
| | Meals | 1 | 2020 | 130 | 0.140 |
Why?
| | Methyldopa | 1 | 2018 | 6 | 0.140 |
Why?
| | Receptor, Cannabinoid, CB1 | 1 | 2018 | 39 | 0.140 |
Why?
| | Organ Culture Techniques | 1 | 2018 | 154 | 0.140 |
Why?
| | Self Efficacy | 1 | 2002 | 411 | 0.140 |
Why?
| | Aminooxyacetic Acid | 1 | 2017 | 1 | 0.140 |
Why?
| | Sodium Channel Agonists | 1 | 2017 | 1 | 0.140 |
Why?
| | Receptors, Adrenergic, beta-3 | 1 | 2017 | 4 | 0.140 |
Why?
| | Sensitivity and Specificity | 4 | 2009 | 1983 | 0.140 |
Why?
| | International Agencies | 1 | 2017 | 30 | 0.140 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2020 | 557 | 0.140 |
Why?
| | Analysis of Variance | 1 | 2020 | 1304 | 0.130 |
Why?
| | Hemoglobin A | 1 | 2017 | 21 | 0.130 |
Why?
| | Injections | 1 | 2018 | 196 | 0.130 |
Why?
| | Malondialdehyde | 1 | 2017 | 30 | 0.130 |
Why?
| | Serum Amyloid A Protein | 1 | 2017 | 32 | 0.130 |
Why?
| | Patient Care Planning | 1 | 2019 | 169 | 0.130 |
Why?
| | Sodium Bicarbonate | 1 | 2018 | 47 | 0.130 |
Why?
| | Glyburide | 1 | 2017 | 31 | 0.130 |
Why?
| | Propanolamines | 1 | 2017 | 40 | 0.130 |
Why?
| | Equivalence Trials as Topic | 1 | 2017 | 35 | 0.130 |
Why?
| | Administration, Oral | 2 | 2017 | 847 | 0.130 |
Why?
| | Methanol | 1 | 2017 | 46 | 0.130 |
Why?
| | Least-Squares Analysis | 1 | 2017 | 76 | 0.130 |
Why?
| | Immunization | 1 | 2019 | 374 | 0.130 |
Why?
| | Alkynes | 1 | 2017 | 66 | 0.130 |
Why?
| | Toll-Like Receptor 9 | 1 | 2017 | 37 | 0.130 |
Why?
| | HLA-DQ Antigens | 1 | 2018 | 173 | 0.130 |
Why?
| | Protein Carbonylation | 1 | 2017 | 57 | 0.130 |
Why?
| | Biomechanical Phenomena | 1 | 2021 | 842 | 0.130 |
Why?
| | Solvents | 1 | 2017 | 113 | 0.130 |
Why?
| | Phytotherapy | 1 | 2017 | 74 | 0.130 |
Why?
| | Data Interpretation, Statistical | 1 | 2019 | 371 | 0.130 |
Why?
| | Adipokines | 1 | 2017 | 57 | 0.130 |
Why?
| | Islet Amyloid Polypeptide | 3 | 2013 | 48 | 0.130 |
Why?
| | Patient Dropouts | 1 | 2017 | 64 | 0.130 |
Why?
| | Patient Compliance | 2 | 2013 | 585 | 0.130 |
Why?
| | Cyclooxygenase 2 | 1 | 2017 | 165 | 0.130 |
Why?
| | Anniversaries and Special Events | 1 | 2017 | 16 | 0.130 |
Why?
| | Fatty Acids, Nonesterified | 1 | 2017 | 158 | 0.130 |
Why?
| | Computer-Aided Design | 1 | 2017 | 40 | 0.130 |
Why?
| | Antigen Presentation | 1 | 2018 | 205 | 0.130 |
Why?
| | Antibodies, Viral | 1 | 2021 | 672 | 0.130 |
Why?
| | Furans | 1 | 2016 | 27 | 0.130 |
Why?
| | Uric Acid | 1 | 2018 | 166 | 0.130 |
Why?
| | Cell Survival | 1 | 2020 | 1098 | 0.120 |
Why?
| | Up-Regulation | 1 | 2020 | 851 | 0.120 |
Why?
| | Clinical Protocols | 1 | 2018 | 282 | 0.120 |
Why?
| | In Vitro Techniques | 2 | 2016 | 1047 | 0.120 |
Why?
| | Indicators and Reagents | 1 | 2016 | 106 | 0.120 |
Why?
| | Sympathomimetics | 1 | 2016 | 19 | 0.120 |
Why?
| | Antibody Formation | 1 | 2018 | 294 | 0.120 |
Why?
| | Oleaceae | 1 | 2016 | 1 | 0.120 |
Why?
| | Piperidines | 1 | 2018 | 217 | 0.120 |
Why?
| | Combined Modality Therapy | 2 | 2017 | 1264 | 0.120 |
Why?
| | Coronary Artery Disease | 3 | 2010 | 741 | 0.120 |
Why?
| | Glycine | 1 | 2017 | 187 | 0.120 |
Why?
| | Antihypertensive Agents | 3 | 2012 | 509 | 0.120 |
Why?
| | Cysteine | 1 | 2017 | 210 | 0.120 |
Why?
| | Socioeconomic Factors | 1 | 2021 | 1312 | 0.120 |
Why?
| | Eating | 3 | 2009 | 389 | 0.120 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2022 | 985 | 0.120 |
Why?
| | Anti-Inflammatory Agents | 1 | 2020 | 474 | 0.120 |
Why?
| | Comorbidity | 1 | 2021 | 1646 | 0.120 |
Why?
| | Amyloid | 2 | 2007 | 92 | 0.120 |
Why?
| | Drug Hypersensitivity | 1 | 2017 | 90 | 0.120 |
Why?
| | Leptin | 2 | 2017 | 244 | 0.120 |
Why?
| | Lung | 1 | 2009 | 4108 | 0.120 |
Why?
| | Vascular Stiffness | 1 | 2021 | 462 | 0.120 |
Why?
| | Aniline Compounds | 1 | 2016 | 119 | 0.120 |
Why?
| | Membrane Potentials | 1 | 2016 | 280 | 0.120 |
Why?
| | Forecasting | 2 | 2016 | 388 | 0.120 |
Why?
| | Drug Design | 1 | 2017 | 173 | 0.120 |
Why?
| | Moringa oleifera | 1 | 2015 | 3 | 0.120 |
Why?
| | Estradiol | 1 | 2019 | 533 | 0.120 |
Why?
| | Pilot Projects | 2 | 2018 | 1867 | 0.120 |
Why?
| | Interleukin-10 | 1 | 2017 | 309 | 0.120 |
Why?
| | Incretins | 1 | 2015 | 21 | 0.120 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2016 | 269 | 0.120 |
Why?
| | Postnatal Care | 1 | 2016 | 72 | 0.110 |
Why?
| | Toll-Like Receptor 4 | 1 | 2017 | 276 | 0.110 |
Why?
| | Imidazoles | 1 | 2016 | 254 | 0.110 |
Why?
| | Interleukin 1 Receptor Antagonist Protein | 2 | 2013 | 253 | 0.110 |
Why?
| | Cells, Cultured | 2 | 2020 | 4146 | 0.110 |
Why?
| | Early Diagnosis | 2 | 2015 | 247 | 0.110 |
Why?
| | RNA, Messenger | 1 | 2023 | 2829 | 0.110 |
Why?
| | Disease Management | 1 | 2019 | 643 | 0.110 |
Why?
| | Materials Testing | 2 | 2017 | 354 | 0.110 |
Why?
| | Cholesterol, HDL | 1 | 2015 | 194 | 0.110 |
Why?
| | Vitamin D Deficiency | 2 | 2020 | 185 | 0.110 |
Why?
| | Estrenes | 1 | 2014 | 17 | 0.100 |
Why?
| | Pyrrolidinones | 1 | 2014 | 29 | 0.100 |
Why?
| | Colesevelam Hydrochloride | 1 | 2013 | 6 | 0.100 |
Why?
| | Gastrins | 1 | 2013 | 8 | 0.100 |
Why?
| | Allylamine | 1 | 2013 | 6 | 0.100 |
Why?
| | Phosphodiesterase Inhibitors | 1 | 2014 | 73 | 0.100 |
Why?
| | Bromocriptine | 1 | 2013 | 31 | 0.100 |
Why?
| | Self-Management | 1 | 2017 | 201 | 0.100 |
Why?
| | Colorado | 2 | 2020 | 4562 | 0.100 |
Why?
| | Sodium-Glucose Transporter 2 | 1 | 2013 | 29 | 0.100 |
Why?
| | Prenatal Care | 1 | 2016 | 306 | 0.100 |
Why?
| | Immunohistochemistry | 1 | 2017 | 1715 | 0.100 |
Why?
| | Catecholamines | 1 | 2013 | 87 | 0.100 |
Why?
| | Staining and Labeling | 1 | 2014 | 150 | 0.100 |
Why?
| | Kidney Diseases | 1 | 2017 | 425 | 0.100 |
Why?
| | Inflammation | 1 | 2005 | 2877 | 0.100 |
Why?
| | Staphylococcus aureus | 1 | 2017 | 454 | 0.100 |
Why?
| | Chemistry, Pharmaceutical | 1 | 2013 | 109 | 0.100 |
Why?
| | Toxicity Tests, Subacute | 1 | 2013 | 1 | 0.100 |
Why?
| | Enzyme Inhibitors | 1 | 2016 | 824 | 0.100 |
Why?
| | Coronary Disease | 2 | 2007 | 381 | 0.100 |
Why?
| | Immunologic Factors | 1 | 2015 | 255 | 0.100 |
Why?
| | Age Factors | 2 | 2019 | 3313 | 0.100 |
Why?
| | Age of Onset | 2 | 2026 | 536 | 0.100 |
Why?
| | Escherichia coli | 1 | 2017 | 852 | 0.100 |
Why?
| | Sitagliptin Phosphate | 1 | 2013 | 31 | 0.100 |
Why?
| | Menopause | 1 | 2016 | 319 | 0.090 |
Why?
| | Cooperative Behavior | 1 | 2016 | 462 | 0.090 |
Why?
| | Thiazolidinediones | 1 | 2013 | 138 | 0.090 |
Why?
| | Oxidation-Reduction | 1 | 2016 | 1084 | 0.090 |
Why?
| | Delayed-Action Preparations | 1 | 2013 | 183 | 0.090 |
Why?
| | Insecticides | 1 | 2013 | 42 | 0.090 |
Why?
| | Patient Selection | 2 | 2009 | 719 | 0.090 |
Why?
| | T-Lymphocytes | 2 | 2018 | 1982 | 0.090 |
Why?
| | Islets of Langerhans Transplantation | 1 | 2013 | 67 | 0.090 |
Why?
| | Leadership | 1 | 2017 | 408 | 0.090 |
Why?
| | Quality of Life | 5 | 2016 | 3166 | 0.090 |
Why?
| | Cross-Sectional Studies | 5 | 2025 | 5813 | 0.090 |
Why?
| | Gene Expression Regulation | 2 | 2019 | 2603 | 0.090 |
Why?
| | Zinc | 1 | 2015 | 294 | 0.090 |
Why?
| | Cell Proliferation | 2 | 2016 | 2494 | 0.090 |
Why?
| | Circadian Rhythm | 4 | 2015 | 513 | 0.090 |
Why?
| | Drinking Water | 1 | 2013 | 97 | 0.090 |
Why?
| | Self Administration | 1 | 2011 | 124 | 0.090 |
Why?
| | Carotenoids | 1 | 2011 | 48 | 0.080 |
Why?
| | Internet | 1 | 2016 | 698 | 0.080 |
Why?
| | Managed Care Programs | 1 | 2011 | 136 | 0.080 |
Why?
| | Swine | 1 | 2013 | 831 | 0.080 |
Why?
| | Cohort Studies | 4 | 2019 | 5935 | 0.080 |
Why?
| | Regression Analysis | 2 | 2010 | 998 | 0.080 |
Why?
| | Eicosapentaenoic Acid | 1 | 2010 | 36 | 0.080 |
Why?
| | Metformin | 1 | 2013 | 315 | 0.080 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2013 | 338 | 0.080 |
Why?
| | Home Care Services | 1 | 2013 | 280 | 0.080 |
Why?
| | Surveys and Questionnaires | 4 | 2014 | 6021 | 0.070 |
Why?
| | Drug Combinations | 1 | 2010 | 390 | 0.070 |
Why?
| | Carcinogens | 1 | 2009 | 122 | 0.070 |
Why?
| | Physicians | 2 | 2017 | 938 | 0.070 |
Why?
| | Decision Making | 2 | 2013 | 974 | 0.070 |
Why?
| | Vital Capacity | 1 | 2009 | 290 | 0.070 |
Why?
| | Disease Progression | 3 | 2012 | 2840 | 0.070 |
Why?
| | Forced Expiratory Volume | 1 | 2009 | 448 | 0.070 |
Why?
| | Hepatitis A Virus Cellular Receptor 1 | 2 | 2018 | 41 | 0.070 |
Why?
| | Immunosuppressive Agents | 1 | 2013 | 846 | 0.070 |
Why?
| | Rats, Sprague-Dawley | 1 | 2013 | 2525 | 0.070 |
Why?
| | C-Reactive Protein | 2 | 2013 | 416 | 0.070 |
Why?
| | Angiotensin II Type 2 Receptor Blockers | 1 | 2007 | 7 | 0.070 |
Why?
| | Norway | 2 | 2019 | 45 | 0.070 |
Why?
| | Medication Adherence | 1 | 2011 | 512 | 0.070 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2007 | 77 | 0.060 |
Why?
| | Drug Costs | 1 | 2008 | 115 | 0.060 |
Why?
| | Sheep | 1 | 2010 | 880 | 0.060 |
Why?
| | Nebulizers and Vaporizers | 1 | 2007 | 62 | 0.060 |
Why?
| | Infusion Pumps, Implantable | 2 | 2004 | 26 | 0.060 |
Why?
| | Risk Management | 2 | 2019 | 84 | 0.060 |
Why?
| | Renin-Angiotensin System | 1 | 2007 | 78 | 0.060 |
Why?
| | Australia | 2 | 2019 | 286 | 0.060 |
Why?
| | Zinc Transporter 8 | 1 | 2026 | 70 | 0.060 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2007 | 221 | 0.060 |
Why?
| | Societies, Medical | 1 | 2010 | 886 | 0.060 |
Why?
| | Creatinine | 2 | 2018 | 505 | 0.060 |
Why?
| | Infant | 1 | 2020 | 10022 | 0.060 |
Why?
| | Alprostadil | 1 | 2005 | 29 | 0.060 |
Why?
| | Attitude of Health Personnel | 1 | 2013 | 1182 | 0.060 |
Why?
| | Patient Acceptance of Health Care | 1 | 2012 | 878 | 0.050 |
Why?
| | Immunity, Humoral | 2 | 2016 | 120 | 0.050 |
Why?
| | Barium Compounds | 1 | 2004 | 12 | 0.050 |
Why?
| | Terbutaline | 1 | 2004 | 8 | 0.050 |
Why?
| | Organ Size | 2 | 2016 | 462 | 0.050 |
Why?
| | Potassium Chloride | 1 | 2004 | 40 | 0.050 |
Why?
| | Abortifacient Agents, Nonsteroidal | 1 | 2004 | 19 | 0.050 |
Why?
| | Receptors, Adrenergic, beta-2 | 1 | 2004 | 35 | 0.050 |
Why?
| | Spermatogenesis | 1 | 2025 | 91 | 0.050 |
Why?
| | Dinoprostone | 1 | 2005 | 178 | 0.050 |
Why?
| | Hyperlipidemias | 1 | 2005 | 121 | 0.050 |
Why?
| | Albuterol | 1 | 2004 | 73 | 0.050 |
Why?
| | Automation | 1 | 2004 | 102 | 0.050 |
Why?
| | Pulmonary Artery | 1 | 2010 | 1134 | 0.050 |
Why?
| | Chlorides | 1 | 2004 | 141 | 0.050 |
Why?
| | Modems | 1 | 2003 | 1 | 0.050 |
Why?
| | Propensity Score | 1 | 2025 | 367 | 0.050 |
Why?
| | Homeostasis | 1 | 2007 | 640 | 0.050 |
Why?
| | Capillaries | 1 | 2004 | 124 | 0.050 |
Why?
| | Food | 1 | 2004 | 149 | 0.050 |
Why?
| | Fetal Macrosomia | 1 | 2003 | 62 | 0.050 |
Why?
| | Transaminases | 1 | 2022 | 22 | 0.050 |
Why?
| | Glycation End Products, Advanced | 1 | 2023 | 82 | 0.050 |
Why?
| | Primary Health Care | 1 | 2013 | 1710 | 0.050 |
Why?
| | Costs and Cost Analysis | 1 | 2003 | 218 | 0.050 |
Why?
| | Congenital Abnormalities | 1 | 2003 | 104 | 0.050 |
Why?
| | Lipoproteins, LDL | 1 | 2022 | 114 | 0.050 |
Why?
| | Educational Status | 1 | 2004 | 464 | 0.050 |
Why?
| | Ketone Bodies | 1 | 2021 | 15 | 0.040 |
Why?
| | Preconception Care | 1 | 2002 | 50 | 0.040 |
Why?
| | Follow-Up Studies | 2 | 2020 | 5389 | 0.040 |
Why?
| | Labor, Obstetric | 1 | 2002 | 66 | 0.040 |
Why?
| | Breath Tests | 1 | 2021 | 79 | 0.040 |
Why?
| | Brain | 1 | 2013 | 2930 | 0.040 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2005 | 434 | 0.040 |
Why?
| | Prognosis | 2 | 2020 | 4278 | 0.040 |
Why?
| | Ketones | 1 | 2021 | 53 | 0.040 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2021 | 117 | 0.040 |
Why?
| | Pregnancy Trimester, Second | 1 | 2020 | 82 | 0.040 |
Why?
| | Learning | 1 | 2004 | 449 | 0.040 |
Why?
| | Birth Weight | 1 | 2003 | 522 | 0.040 |
Why?
| | Self Concept | 1 | 2002 | 252 | 0.040 |
Why?
| | Immunoglobulin Fc Fragments | 1 | 2020 | 41 | 0.040 |
Why?
| | Gestational Age | 1 | 2003 | 975 | 0.040 |
Why?
| | Vascular Resistance | 1 | 2021 | 366 | 0.040 |
Why?
| | Skin | 1 | 2004 | 754 | 0.040 |
Why?
| | Polyunsaturated Alkamides | 1 | 2019 | 8 | 0.040 |
Why?
| | Capsaicin | 1 | 2019 | 30 | 0.040 |
Why?
| | Arachidonic Acids | 1 | 2019 | 43 | 0.040 |
Why?
| | Immunoblotting | 1 | 2019 | 300 | 0.040 |
Why?
| | Postpartum Period | 1 | 2002 | 361 | 0.040 |
Why?
| | Data Accuracy | 1 | 2019 | 65 | 0.040 |
Why?
| | Databases, Factual | 1 | 2004 | 1484 | 0.040 |
Why?
| | Internationality | 1 | 2019 | 156 | 0.040 |
Why?
| | Microscopy, Polarization | 1 | 2018 | 31 | 0.030 |
Why?
| | Osmolar Concentration | 1 | 2018 | 167 | 0.030 |
Why?
| | Sodium | 1 | 2019 | 197 | 0.030 |
Why?
| | Retinol-Binding Proteins, Plasma | 1 | 2017 | 6 | 0.030 |
Why?
| | Resistin | 1 | 2017 | 11 | 0.030 |
Why?
| | Lipocalin-2 | 1 | 2017 | 79 | 0.030 |
Why?
| | North America | 1 | 2018 | 310 | 0.030 |
Why?
| | Multicenter Studies as Topic | 1 | 2019 | 402 | 0.030 |
Why?
| | Lost to Follow-Up | 1 | 2017 | 18 | 0.030 |
Why?
| | Survival Rate | 1 | 2022 | 2088 | 0.030 |
Why?
| | Fatty Acid-Binding Proteins | 1 | 2017 | 79 | 0.030 |
Why?
| | Recombinant Fusion Proteins | 1 | 2020 | 674 | 0.030 |
Why?
| | Seminiferous Tubules | 1 | 2016 | 13 | 0.030 |
Why?
| | Sleep | 2 | 2015 | 901 | 0.030 |
Why?
| | Semen | 1 | 2016 | 23 | 0.030 |
Why?
| | Hypersensitivity, Delayed | 1 | 2016 | 29 | 0.030 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2018 | 561 | 0.030 |
Why?
| | Drug Resistance | 1 | 2017 | 153 | 0.030 |
Why?
| | Mice, Inbred NOD | 1 | 2018 | 610 | 0.030 |
Why?
| | Polymorphism, Genetic | 2 | 2010 | 612 | 0.030 |
Why?
| | Cost Savings | 1 | 2016 | 86 | 0.030 |
Why?
| | Edema | 1 | 2016 | 124 | 0.030 |
Why?
| | Models, Economic | 1 | 2016 | 62 | 0.030 |
Why?
| | Research Personnel | 1 | 2017 | 183 | 0.030 |
Why?
| | Adiponectin | 1 | 2017 | 243 | 0.030 |
Why?
| | Equipment and Supplies | 1 | 2015 | 35 | 0.030 |
Why?
| | Antibodies, Bacterial | 1 | 2016 | 148 | 0.030 |
Why?
| | Physician-Patient Relations | 1 | 2020 | 581 | 0.030 |
Why?
| | Kidney | 1 | 2023 | 1495 | 0.030 |
Why?
| | Flowers | 1 | 2016 | 70 | 0.030 |
Why?
| | Gas Chromatography-Mass Spectrometry | 1 | 2015 | 131 | 0.030 |
Why?
| | Body Burden | 1 | 2015 | 7 | 0.030 |
Why?
| | Interleukin-2 | 1 | 2016 | 437 | 0.030 |
Why?
| | C-Peptide | 1 | 2015 | 186 | 0.030 |
Why?
| | Salmonella typhimurium | 1 | 2016 | 190 | 0.030 |
Why?
| | Consensus | 1 | 2016 | 488 | 0.030 |
Why?
| | Communication | 1 | 2020 | 961 | 0.030 |
Why?
| | Genotype | 2 | 2010 | 1833 | 0.030 |
Why?
| | Academic Medical Centers | 1 | 2017 | 545 | 0.030 |
Why?
| | Neoplasms | 1 | 2009 | 2870 | 0.030 |
Why?
| | Drug Monitoring | 1 | 2017 | 389 | 0.020 |
Why?
| | Delivery of Health Care | 1 | 2020 | 940 | 0.020 |
Why?
| | Liver | 1 | 2022 | 1884 | 0.020 |
Why?
| | Prenatal Diagnosis | 1 | 2015 | 195 | 0.020 |
Why?
| | Activities of Daily Living | 1 | 2017 | 440 | 0.020 |
Why?
| | Cost-Benefit Analysis | 1 | 2016 | 623 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 850 | 0.020 |
Why?
| | Data Display | 1 | 2013 | 20 | 0.020 |
Why?
| | E-Selectin | 1 | 2013 | 61 | 0.020 |
Why?
| | Chemokine CXCL10 | 1 | 2013 | 39 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2018 | 2182 | 0.020 |
Why?
| | Testosterone | 1 | 2016 | 419 | 0.020 |
Why?
| | Risk | 1 | 2015 | 909 | 0.020 |
Why?
| | Electronic Health Records | 1 | 2020 | 1169 | 0.020 |
Why?
| | Statistics as Topic | 1 | 2013 | 281 | 0.020 |
Why?
| | Bone and Bones | 1 | 2015 | 313 | 0.020 |
Why?
| | Interleukin-6 | 1 | 2016 | 780 | 0.020 |
Why?
| | Health Services Accessibility | 1 | 2020 | 1091 | 0.020 |
Why?
| | Tetraethylammonium | 1 | 2011 | 16 | 0.020 |
Why?
| | beta Carotene | 1 | 2011 | 20 | 0.020 |
Why?
| | Vitamin A | 1 | 2011 | 59 | 0.020 |
Why?
| | Phenotype | 1 | 2019 | 3157 | 0.020 |
Why?
| | Receptors, Calcitriol | 1 | 2010 | 55 | 0.020 |
Why?
| | Calcium Chloride | 1 | 2010 | 11 | 0.020 |
Why?
| | Expert Testimony | 1 | 2010 | 42 | 0.020 |
Why?
| | Serotonin Antagonists | 1 | 2010 | 30 | 0.020 |
Why?
| | Cholesterol | 1 | 2012 | 399 | 0.020 |
Why?
| | Nitrites | 1 | 2010 | 89 | 0.020 |
Why?
| | Benzimidazoles | 1 | 2011 | 190 | 0.020 |
Why?
| | Intracellular Space | 1 | 2010 | 66 | 0.020 |
Why?
| | B-Lymphocytes | 1 | 2015 | 876 | 0.020 |
Why?
| | Extracellular Space | 1 | 2010 | 120 | 0.020 |
Why?
| | Potassium | 1 | 2010 | 152 | 0.020 |
Why?
| | Nitric Oxide Synthase | 1 | 2010 | 235 | 0.020 |
Why?
| | Vasoconstrictor Agents | 1 | 2010 | 144 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 981 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2017 | 2917 | 0.020 |
Why?
| | Serotonin | 1 | 2010 | 293 | 0.020 |
Why?
| | Angiotensins | 1 | 2007 | 8 | 0.020 |
Why?
| | Receptor, Angiotensin, Type 1 | 1 | 2007 | 25 | 0.020 |
Why?
| | Peptidyl-Dipeptidase A | 1 | 2007 | 56 | 0.020 |
Why?
| | Insurance, Health, Reimbursement | 1 | 2007 | 95 | 0.020 |
Why?
| | Fatty Acids | 1 | 2010 | 450 | 0.020 |
Why?
| | Long-Term Care | 1 | 2007 | 117 | 0.020 |
Why?
| | Peptides | 1 | 2011 | 995 | 0.010 |
Why?
| | Models, Biological | 1 | 2013 | 1820 | 0.010 |
Why?
| | Fructosamine | 1 | 2005 | 11 | 0.010 |
Why?
| | Predictive Value of Tests | 1 | 2010 | 2111 | 0.010 |
Why?
| | Hemoglobins | 1 | 2007 | 383 | 0.010 |
Why?
| | Age Distribution | 1 | 2005 | 397 | 0.010 |
Why?
| | Sex Distribution | 1 | 2005 | 380 | 0.010 |
Why?
| | Hemoglobinuria | 1 | 2003 | 5 | 0.010 |
Why?
| | Tomography, X-Ray Computed | 2 | 2003 | 2730 | 0.010 |
Why?
| | Logistic Models | 1 | 2003 | 2104 | 0.010 |
Why?
| | Sex Characteristics | 1 | 2003 | 789 | 0.010 |
Why?
| | Insulin Resistance | 1 | 2003 | 1232 | 0.010 |
Why?
|
|
Garg's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|